Concepedia

Chuan Xing Wu

CX

Statistics

Publications

4

Citations

382

H-Index

4

Active since

2017

Affiliations

University of Hong Kong(Current)

Pfizer (United States)

Chuan Xing Wu is an author at University of Hong Kong specializing in medicine, oncology, and cancer pharmacology.

Publications per year

2017–2018

4

Publications

4

Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma

Chuan Xing Wu, Xiao Qi Wang, Kwan Man et al. · Theranostics · 2018 · 237 citations · Full text

Medicine, Oncology, Pharmacology +17

Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1–Stat3

Chuan Xing Wu, Ai‐Min Xu, Cathy C. Zhang et al. · Molecular Cancer Therapeutics · 2017 · 86 citations · Full text

Medicine, Oncology, Pharmacology +17

Identification of the histone lysine demethylase KDM4A/JMJD2A as a novel epigenetic target in M1 macrophage polarization induced by oxidized LDL

Xue Wang, Siqing Wang, Gang Yao et al. · Oncotarget · 2017 · 34 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma

Xuran Yang, Wei Xia, Lin Chen et al. · Oncotarget · 2018 · 25 citations · Full text

Medicine, Oncology, Pharmacology +13

1–4 of 4